ClotCare: Blood Clots, Stroke, Heart Attack
Monday, May 27, 2024
Home   |   DVT/PE   |   Blood Clots   |   Coumadin/Warfarin   |   New Patients   |   Self Testing   |   Email List   |   Donate

Pick a Topic:

Find info on a:

We subscribe to the HONcode principles of the HON Foundation. Click to verify.
ClotCare complies with the HONcode standard for trustworthy health
verify here.

ClotCare is a member of the Coalition to Prevent Deep Vein Thrombosis (DVT Coalition)  ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.

ProFESS gives new direction for selection of antiplatelet therapies for stroke patients

Susan C. Fagan, Pharm.D., BCPS, FCCP
November, 2008

Although the results of noncomparative clinical trials led experts in the stroke field to prefer the combination of aspirin and extended release dipyridamole (ERDP) over clopidogrel or aspirin for secondary prevention of noncardioembolic stroke, all three agents were first line in recent guidelines.1 Anticipation was high that the ProFESS trial, comparing clopidogrel and the combination of aspirin and ERDP for prevention of recurrent stroke, would be the definitive answer to the selection process.

ProFESS was the largest stroke trial ever performed with more than 20,000 patients enrolled in 35 different countries.2 Using a 2x2 factorial design, the investigators compared the two antiplatelet agents and an angiotensin receptor blocker (ARB) (telmisartan) to placebo. To everyone’s surprise, there were absolutely no differences in recurrent stroke rates between the treatments (9% over 2.5 years). Even in the ARB arm, where prior publications suggested that ARBs would provide vascular protection, there was no difference. Also, even though some expected a lower bleeding rate in the aspirin/ERDP group, this was not the case - clopidogrel was at least as safe.

The bottom line of the ProFESS trial, was that clopidogrel and aspirin/ERDP are not different in their efficacy and both agents are safe. As a result of this trial, we will probably see a resurgence in the use of clopidogrel (without aspirin) as a secondary prevention strategy in ischemic stroke patients.


Ask a question about blood clots or anticoagulant medications Have questions? Ask ClotCare. Send questions by email to

ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters.

Blood Clot Activities Calendar

New Postings:

Click here to view full list of new postings
ClotCare Home | New Postings | Patient Postings | Clinician Postings | Join Our Email List | Useful Web Links
CE Opportunities | Training Programs | DVT & PE Stories | Editorial Board | Financial Support
About ClotCare | DVT Coalition | Donate to ClotCare | Contact Us
Key topics discussed on ClotCare include: Blood Clots | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Atrial Fibrillation (A. Fib or AF) | Heart Attack | Stroke | Transient Ischemic Attack (TIA) | Mini Stroke | Bleeding Complications | Vascular Surgery | Surgical Blood Clot Removal | Warfarin | Coumadin | Lovenox | Low Molecular Weight Heparin (LMWH) | Heparin | Anticoagulants | Plavix | Aspirin | Antiplatelets | Blood Thinners
Copyright 2000-2018 by ClotCare. All rights reserved.
Terms, Conditions, & Privacy | Image Copyright Information
19260 Stone Oak Parkway, Suite 101 | San Antonio, TX 78258 | 210-860-0487
Send comments to
Monday, May 27, 2024